|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DR1 |
Gene summary for DR1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DR1 | Gene ID | 1810 |
| Gene name | down-regulator of transcription 1 | |
| Gene Alias | NC2 | |
| Cytomap | 1p22.1 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q01658 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1810 | DR1 | LZE4T | Human | Esophagus | ESCC | 1.67e-11 | 1.98e-01 | 0.0811 |
| 1810 | DR1 | LZE5T | Human | Esophagus | ESCC | 7.01e-04 | 1.10e-01 | 0.0514 |
| 1810 | DR1 | LZE8T | Human | Esophagus | ESCC | 1.60e-02 | -8.08e-02 | 0.067 |
| 1810 | DR1 | LZE20T | Human | Esophagus | ESCC | 4.18e-07 | 1.65e-01 | 0.0662 |
| 1810 | DR1 | LZE22T | Human | Esophagus | ESCC | 2.43e-03 | 2.40e-01 | 0.068 |
| 1810 | DR1 | LZE24T | Human | Esophagus | ESCC | 2.94e-10 | 4.24e-01 | 0.0596 |
| 1810 | DR1 | P2T-E | Human | Esophagus | ESCC | 7.94e-36 | 6.94e-01 | 0.1177 |
| 1810 | DR1 | P4T-E | Human | Esophagus | ESCC | 4.76e-23 | 3.55e-01 | 0.1323 |
| 1810 | DR1 | P5T-E | Human | Esophagus | ESCC | 4.54e-26 | 6.38e-01 | 0.1327 |
| 1810 | DR1 | P8T-E | Human | Esophagus | ESCC | 1.15e-22 | 3.52e-01 | 0.0889 |
| 1810 | DR1 | P9T-E | Human | Esophagus | ESCC | 2.00e-16 | 2.70e-01 | 0.1131 |
| 1810 | DR1 | P10T-E | Human | Esophagus | ESCC | 1.51e-36 | 7.30e-01 | 0.116 |
| 1810 | DR1 | P11T-E | Human | Esophagus | ESCC | 2.61e-11 | 5.52e-01 | 0.1426 |
| 1810 | DR1 | P12T-E | Human | Esophagus | ESCC | 1.79e-84 | 2.02e+00 | 0.1122 |
| 1810 | DR1 | P15T-E | Human | Esophagus | ESCC | 4.18e-26 | 6.79e-01 | 0.1149 |
| 1810 | DR1 | P16T-E | Human | Esophagus | ESCC | 3.22e-27 | 2.94e-01 | 0.1153 |
| 1810 | DR1 | P17T-E | Human | Esophagus | ESCC | 3.09e-05 | 4.32e-01 | 0.1278 |
| 1810 | DR1 | P19T-E | Human | Esophagus | ESCC | 1.27e-06 | 8.87e-01 | 0.1662 |
| 1810 | DR1 | P20T-E | Human | Esophagus | ESCC | 6.66e-28 | 7.21e-01 | 0.1124 |
| 1810 | DR1 | P21T-E | Human | Esophagus | ESCC | 1.01e-20 | 1.98e-01 | 0.1617 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00064734 | Oral cavity | OSCC | protein acetylation | 124/7305 | 201/18723 | 5.59e-11 | 1.74e-09 | 124 |
| GO:190290320 | Oral cavity | OSCC | regulation of supramolecular fiber organization | 211/7305 | 383/18723 | 9.45e-11 | 2.88e-09 | 211 |
| GO:005149518 | Oral cavity | OSCC | positive regulation of cytoskeleton organization | 135/7305 | 226/18723 | 1.98e-10 | 5.66e-09 | 135 |
| GO:00069037 | Oral cavity | OSCC | vesicle targeting | 38/7305 | 45/18723 | 4.49e-10 | 1.19e-08 | 38 |
| GO:00516509 | Oral cavity | OSCC | establishment of vesicle localization | 101/7305 | 161/18723 | 8.79e-10 | 2.17e-08 | 101 |
| GO:000716318 | Oral cavity | OSCC | establishment or maintenance of cell polarity | 129/7305 | 218/18723 | 1.16e-09 | 2.86e-08 | 129 |
| GO:00165734 | Oral cavity | OSCC | histone acetylation | 96/7305 | 152/18723 | 1.35e-09 | 3.29e-08 | 96 |
| GO:00183934 | Oral cavity | OSCC | internal peptidyl-lysine acetylation | 99/7305 | 158/18723 | 1.41e-09 | 3.39e-08 | 99 |
| GO:00064754 | Oral cavity | OSCC | internal protein amino acid acetylation | 100/7305 | 160/18723 | 1.43e-09 | 3.41e-08 | 100 |
| GO:00004706 | Oral cavity | OSCC | maturation of LSU-rRNA | 26/7305 | 28/18723 | 3.39e-09 | 7.66e-08 | 26 |
| GO:00356014 | Oral cavity | OSCC | protein deacylation | 74/7305 | 112/18723 | 5.88e-09 | 1.26e-07 | 74 |
| GO:00310567 | Oral cavity | OSCC | regulation of histone modification | 94/7305 | 152/18723 | 9.57e-09 | 1.99e-07 | 94 |
| GO:000701520 | Oral cavity | OSCC | actin filament organization | 230/7305 | 442/18723 | 1.37e-08 | 2.77e-07 | 230 |
| GO:003297020 | Oral cavity | OSCC | regulation of actin filament-based process | 209/7305 | 397/18723 | 1.89e-08 | 3.72e-07 | 209 |
| GO:003158917 | Oral cavity | OSCC | cell-substrate adhesion | 193/7305 | 363/18723 | 2.48e-08 | 4.82e-07 | 193 |
| GO:004873220 | Oral cavity | OSCC | gland development | 226/7305 | 436/18723 | 2.78e-08 | 5.39e-07 | 226 |
| GO:00516489 | Oral cavity | OSCC | vesicle localization | 105/7305 | 177/18723 | 3.30e-08 | 6.30e-07 | 105 |
| GO:001081019 | Oral cavity | OSCC | regulation of cell-substrate adhesion | 126/7305 | 221/18723 | 4.02e-08 | 7.55e-07 | 126 |
| GO:003253519 | Oral cavity | OSCC | regulation of cellular component size | 201/7305 | 383/18723 | 4.80e-08 | 8.88e-07 | 201 |
| GO:00987324 | Oral cavity | OSCC | macromolecule deacylation | 74/7305 | 116/18723 | 5.52e-08 | 1.01e-06 | 74 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DR1 | SNV | Missense_Mutation | novel | c.25N>A | p.Asp9Asn | p.D9N | Q01658 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
| DR1 | SNV | Missense_Mutation | c.145N>A | p.Leu49Ile | p.L49I | Q01658 | protein_coding | deleterious(0.02) | probably_damaging(0.92) | TCGA-CA-6715-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR | |
| DR1 | SNV | Missense_Mutation | c.146N>G | p.Leu49Arg | p.L49R | Q01658 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DR1 | SNV | Missense_Mutation | c.328N>C | p.Asn110His | p.N110H | Q01658 | protein_coding | tolerated(0.08) | benign(0.222) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| DR1 | SNV | Missense_Mutation | novel | c.253N>G | p.Ser85Gly | p.S85G | Q01658 | protein_coding | tolerated(0.29) | benign(0.04) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DR1 | SNV | Missense_Mutation | c.161N>T | p.Ala54Val | p.A54V | Q01658 | protein_coding | deleterious(0.02) | possibly_damaging(0.668) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| DR1 | SNV | Missense_Mutation | novel | c.41C>T | p.Pro14Leu | p.P14L | Q01658 | protein_coding | deleterious(0) | possibly_damaging(0.618) | TCGA-AX-A3FT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DR1 | SNV | Missense_Mutation | rs182894486 | c.403G>A | p.Glu135Lys | p.E135K | Q01658 | protein_coding | tolerated(0.16) | possibly_damaging(0.522) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| DR1 | SNV | Missense_Mutation | c.472G>A | p.Ala158Thr | p.A158T | Q01658 | protein_coding | tolerated(0.38) | probably_damaging(0.956) | TCGA-BK-A0C9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| DR1 | SNV | Missense_Mutation | c.516N>A | p.Asp172Glu | p.D172E | Q01658 | protein_coding | tolerated_low_confidence(0.32) | benign(0) | TCGA-D1-A176-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |